<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164864</url>
  </required_header>
  <id_info>
    <org_study_id>1160.186</org_study_id>
    <secondary_id>2013-003201-26</secondary_id>
    <nct_id>NCT02164864</nct_id>
  </id_info>
  <brief_title>Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)</brief_title>
  <official_title>A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus Clopidogrel or Ticagrelor and Aspirin in Patients With Non Valvular Atrial Fibrillation (NVAF) That Have Undergone a Percutaneous Coronary Intervention (PCI) With Stenting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare a Dual Antithrombotic Therapy (DAT) regimen of
      110mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (110mg dabigatran etexilate
      (DE) DAT) and 150mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (150mg DE-DAT)
      with a Triple Antithrombotic Therapy (TAT) combination of warfarin plus clopidogrel or
      ticagrelor plus Aspirin (ASA) &lt;= 100mg once daily (warfarin-TAT) in patients with Atrial
      Fibrillation that undergo a PCI with stenting (elective or due to an Acute Coronary
      Syndrome).

      The study aims to show non-inferiority of each dose of DE-DAT when compared to Warfarin-TAT
      in terms of safety. Safety will be determined by comparing the rates of bleeding events,
      assessed using the modified International Society of Thrombosis and Haemostasis
      classification of Major Bleeding and Clinically Relevant Non Major Bleeding Events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2014</start_date>
  <completion_date type="Actual">June 5, 2017</completion_date>
  <primary_completion_date type="Actual">June 5, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Adjudicated ISTH MBE or CRNMBE</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported.
Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial.
Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status.
Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Adjudicated Undetermined Cause of Death</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported.
This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was &quot;patient died&quot;) or when there was insufficient supporting information or detail to assign the cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Adjudicated Non-CV</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported.
Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Adjudicated CV</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported.
CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Adjudicated All Cause Death</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Adjudicated MI</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Adjudicated Stroke</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported.
Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Adjudicated SE</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported.
SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Adjudicated ST</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Composite Endpoint of Death + MI + Stroke</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Composite Endpoint of Death or First Thrombotic Event</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Adjudicated Unplanned Revascularisation by PCI/CABG</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2725</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Dabigatran Etexilate 110mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive Dabigatran Etexilate 110mg twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran Etexilate 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive Dabigatran Etexilate 150mg twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin doses to maintain INR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Etexilate 110mg</intervention_name>
    <description>Active treatment</description>
    <arm_group_label>Dabigatran Etexilate 110mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin 3mg</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Etexilate 150mg</intervention_name>
    <description>Active treatment</description>
    <arm_group_label>Dabigatran Etexilate 150mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel or Ticagrelor</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel or Ticagrelor</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Dabigatran Etexilate 110mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin 5mg</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel or Ticagrelor</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Dabigatran Etexilate 150mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin 1mg</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female patients aged &gt;=18 years

          -  Patients with Non Valvular Atrial Fibrillation

          -  Patient presenting with:

        An Acute Coronary Syndrome (ACS) (ST elevation myocardial infarction (STEMI), NonSTEMI
        [NSTEMI] or unstable angina [UA]) that was successfully treated by PCI and stenting (either
        Bare Metal Stent (BMS) or Drug Eluting Stent) Or Stable Coronary Artery Disease with at
        least one lesion eligible for PCI that was successfully treated by elective PCI and
        stenting (either BMS or DES)

          -  The patient must be able to give informed consent in accordance with International
             Conference on Harmonisation Good Clinical Practice guidelines and local legislation
             and/or regulations.

        Exclusion criteria:

          -  Patients with a mechanical or biological heart valve prosthesis

          -  Cardiogenic shock during current hospitalisation

          -  Stroke within 1 month prior to screening visit

          -  Patients who have had major surgery within the month prior to screening

          -  Gastrointestinal haemorrhage within one month prior to screening, unless, in the
             opinion of the Investigator, the cause has been permanently eliminated

          -  Major bleeding episode including life-threatening bleeding episode in one month prior
             to screening visit

          -  Anaemia (haemoglobin &lt;10g/dL) or thrombocytopenia including heparin-induced
             thrombocytopenia (platelet count &lt;100 x 109/L) at screening

          -  Severe renal impairment (estimated Creatinine Clearance (CrCl) calculated by
             Cockcroft-Gault equation) &lt;30mL/min at screening

          -  Active liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Verde Valley Medical Center</name>
      <address>
        <city>Cottonwood</city>
        <state>Arizona</state>
        <zip>86326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of Mesa</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Cardiology, PA</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Cardiovascular Research Institute</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Denver Cardiology Associates, PC</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Clinic, LLP</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Center</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiovascular Research and Education Foundation</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ball Memorial Hospital</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Cardiology Associates Research, LLC</name>
      <address>
        <city>Richmond</city>
        <state>Indiana</state>
        <zip>47374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Cod Research Institute</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Michigan Medical Center</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covenant Medical Center, Inc.</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Medical Center dba Essentia Health Saint Mary's Medical Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraCare Heart and Vascular Center</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Veterans Administration Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Anthony's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michaels Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lourdes Cardiology Services</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Western New York Healthcare System</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Heart and Vascular Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Health System</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chambersburg Hospital</name>
      <address>
        <city>Chambersburg</city>
        <state>Pennsylvania</state>
        <zip>17201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Harrisburg Hospital</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Heart Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jackson Clinic, PA</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Dallas Research Associates</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Healthcare</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Cardiovascular Consultants</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wichita Falls Heart Clinic</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayview Physicians Services PC dba Cardiovascular Associates</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Family Memorial, Inc</name>
      <address>
        <city>Manitowoc</city>
        <state>Wisconsin</state>
        <zip>54220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Favaloro</name>
      <address>
        <city>Caba</city>
        <zip>C1093AAS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Caba</city>
        <zip>C1199ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Cardiovascular de Buenos Aires</name>
      <address>
        <city>Caba</city>
        <zip>C1428DCO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorios Asociados de Endocrinología e Invest Clínica</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1425AGC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiología de Corrientes</name>
      <address>
        <city>Corrientes</city>
        <zip>W3400AMZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>Córdoba</city>
        <zip>X5000BFB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto CER</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878DVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst.Cardiovascular San Luis</name>
      <address>
        <city>San Luis</city>
        <zip>D5702JRS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigaciones Clinicas Tucumán</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <zip>T4000ICL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pendlebury Research</name>
      <address>
        <city>Adamstown</city>
        <state>New South Wales</state>
        <zip>2289</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wollongong Hospital</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartcare Victoria</name>
      <address>
        <city>Bundoora</city>
        <state>Victoria</state>
        <zip>3083</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Order Hospital Elisabethinen Linz</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Salzburg, Univ. Clinic</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalst - HOSP Onze-Lieve-Vrouw</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bonheiden - HOSP Imelda</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brussels-UNIV Brugmann -Horta</name>
      <address>
        <city>Brussel</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brussels - UNIV UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas - Campus Sint Lucas</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleroi - HOSP St-Joseph</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Middelheim</name>
      <address>
        <city>Middelheim</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint-Niklaas - HOSP AZ Nikolaas (Campus St-Niklaas)</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tienen - PRAC De Wolf, Axel</name>
      <address>
        <city>Tienen</city>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brussels - HOSP Europe (Ste-Elisabeth)</name>
      <address>
        <city>Ukkel</city>
        <zip>1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Isabel</name>
      <address>
        <city>Blumenau</city>
        <zip>89010-500</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericordia de Curitiba</name>
      <address>
        <city>Campina Grande do Sul</city>
        <zip>83430-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90620-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base - Fac Med de Sao Jose do Rio Preto</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Paulo - UNIFESP</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INCOR e Hospital das Clínicas da Universidade de São Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eurolatino pesquisas Médicas Ltda</name>
      <address>
        <city>Uberlandia</city>
        <zip>38411-186</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Deva Maria&quot;, Dept. of Cardiology, Burgas</name>
      <address>
        <city>Burgas</city>
        <zip>8127</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHAT in Cardiology EAD, Pleven</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT&quot;Sv.Georgi&quot;,Cardi.Clin.</name>
      <address>
        <city>Plovdiv</city>
        <zip>4001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Sv. Vrach&quot; EOOD, Cardiology Dept., Sandanski</name>
      <address>
        <city>Sandanski</city>
        <zip>2800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clin.Univ.MPHAT EOOD,Clin.of Cardiology, Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hosp.f.Active Treatment, Cardiology Dept, Yambol</name>
      <address>
        <city>Yambol</city>
        <zip>8600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calgary Heart Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawartha Cardiology Clinical Trials</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. R. Labonte Prof. Med. Corp</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 3B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Science Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCPQ (Laval University)</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>GLV 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios</name>
      <address>
        <city>Santiago</city>
        <zip>8350488</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Clinicos Barros Luco</name>
      <address>
        <city>Santiago</city>
        <zip>8910131</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Las Higueras</name>
      <address>
        <city>Talcahuano</city>
        <zip>4270918</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CECMI Ltda</name>
      <address>
        <city>Temuco</city>
        <zip>4813299</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Clínica Abood Shaio</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Santa Fe de Bogotá</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Imbanaco de Cali S.A.</name>
      <address>
        <city>Cali</city>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Valle de Lili</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Cardiovascular de Colombia</name>
      <address>
        <city>Floridablanca</city>
        <zip>680004</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobón Uribe</name>
      <address>
        <city>Medellin</city>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clincal Hospital Centre Rijeka</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hosp.Merkur,Clin.Internal Med,Cardiology Dep,Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Sstre Milosrdnice, Cardiology Dept, Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Dubrava</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amkardia, s.r.o. Brno</name>
      <address>
        <city>Brno</city>
        <zip>63900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Jihlava</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karlovarska Reg.Hosp, Cardiology Dept, Karlovy Vary</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>36001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>728 80</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Faculty Hospital, Prague</name>
      <address>
        <city>Praha</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Slany, Internal Department</name>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitals of Pardubice Region, Internal Department, Svitavy</name>
      <address>
        <city>Svitavy</city>
        <zip>568 25</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masaryk Hospital, Usti nad Labem</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp.of Pardubice Reg,Orlickoustecka,Internal Dept, Ustinad</name>
      <address>
        <city>Usti nad Orlici</city>
        <zip>562 18</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Århus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HYKS, Kardiologian klinikka, Sydän- ja keuhkokeskus</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>StudyCor Oy</name>
      <address>
        <city>Jyväskylä</city>
        <zip>42620</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keski-Pohjanmaan keskussairaala, Kardiologian pkl, Kokkola</name>
      <address>
        <city>Kokkola</city>
        <zip>67200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TYKS</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP de la Cavale Blanche</name>
      <address>
        <city>Brest Cedex 2</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Gabriel-Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP St Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLI du Pont de Chaume</name>
      <address>
        <city>Montauban</city>
        <zip>82000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Salpêtrière, Cardio, Paris</name>
      <address>
        <city>Paris cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLI Saint-Hilaire</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn GmbH</name>
      <address>
        <city>Bad Friedrichshall</city>
        <zip>74177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik, Bad Nauheim</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIMS Studienzentrum Bamberg GmbH</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Netzwerk für Gesundheit GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Netzwerk für Gesundheit GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld gGmbH</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josef- und St. Elisabeth-Hospital gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn AöR</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus, Celle</name>
      <address>
        <city>Celle</city>
        <zip>29223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg gGmbH</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Amper-Klinikum Dachau</name>
      <address>
        <city>Dachau</city>
        <zip>85221</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Herz und Gefäße</name>
      <address>
        <city>Dresden</city>
        <zip>01324</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum, Fulda</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefäßzentrum (HGZ-Göttingen) am Krankenhaus Neu Bethlehem</name>
      <address>
        <city>Göttingen</city>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen, Georg-August-Universität</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiologicum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22041</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPK-Heidelberger Praxisklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westküstenkliniken Brunsbüttel und Heide gGmbH</name>
      <address>
        <city>Heide</city>
        <zip>25746</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Langen-Seligenstadt GmbH</name>
      <address>
        <city>Langen</city>
        <zip>63225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein gGmbH</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Märkische Gesundheitsholding GmbH &amp; Co. KG, Klinikum Lüdenscheid</name>
      <address>
        <city>Lüdenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg AöR</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carl-von-Basedow Klinikum Saalekreis gGmgH</name>
      <address>
        <city>Merseburg</city>
        <zip>06217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München - Campus Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum München GmbH</name>
      <address>
        <city>München</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum München GmbH</name>
      <address>
        <city>München</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz-Krankenhaus GmbH</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana-Klinikum Remscheid GmbH</name>
      <address>
        <city>Remscheid</city>
        <zip>42859</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus GmbH</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien-Hospital-Wesel gGmbH</name>
      <address>
        <city>Wesel</city>
        <zip>46483</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Universitätsklinikum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>42117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Alexandroupolis</name>
      <address>
        <city>Alexandroupoli</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration Hospital, Univ Clinic of Cardiology</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Alexandra&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Konstantopoulio-Agia Olga</name>
      <address>
        <city>Athens</city>
        <zip>14233</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Attica &quot;Sismanoglio - Amalia Fleming&quot;</name>
      <address>
        <city>Athens</city>
        <zip>15126</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chios, Department of Cardiology</name>
      <address>
        <city>Chios</city>
        <zip>82100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Heraklion, Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Gen. Hosp. of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Thessaloniki AHEPA</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hosp, Dept of Med &amp; Therapeutics</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen Gyorgy Hungarian Instit.of Cardiology,Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milit.Hosp.-State Health Cent.</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Debrecen Hospital</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Onkormanyzat Hospital</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pecs, Invasive Cardiology</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Szeged, 2nd Dept. of Internal Med., Haematology</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Institute Of Medical Sciences</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medanta- The Medicity</name>
      <address>
        <city>Gurgaon</city>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizam's Institute of Medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B and M Patel Cardiac Centre, Shree Krishna Hospital,</name>
      <address>
        <city>Karamsad</city>
        <zip>388325</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shri Krishna Hrudayalaya and Critical Care</name>
      <address>
        <city>Nagpur</city>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vijan Cardiac and Critical Care Centre</name>
      <address>
        <city>Nasik</city>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fortis Escorts Heart Institute</name>
      <address>
        <city>New Delhi</city>
        <zip>110025</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Byramjee Jeejeebhoy Medical College</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George's Hospital,</name>
      <address>
        <city>Seemandhra</city>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <zip>GALWAY</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center, Hadera</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center, Jerusalem 91031</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West.Galilee Med.Cent.Naharia</name>
      <address>
        <city>Naharia</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center Beilinson</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Donato di Arezzo</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII - A.O. Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fond. Poliambulanza Istituto</name>
      <address>
        <city>Brescia</city>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Clin. SS. Anunziata</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Fabrizio Spaziani&quot;</name>
      <address>
        <city>Frosinone</city>
        <zip>03100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale della Misericordia</name>
      <address>
        <city>Grosseto</city>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Pediatrico Aprano Pasquinucci</name>
      <address>
        <city>Massa</city>
        <zip>54100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pol. Universitario Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00195</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Saronno</name>
      <address>
        <city>Saronno (VA)</city>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bolognini</name>
      <address>
        <city>Seriate</city>
        <zip>24068</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Molinette, AO Città della Salute e della</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Nagoya Daini Hospital</name>
      <address>
        <city>Aichi, Nagoya</city>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirosaki University Hospital</name>
      <address>
        <city>Aomori, Hirosaki</city>
        <zip>036-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba, Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Fukuoka, Kitakyushu</city>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka-Higashi Med. Ctr. Fukuoka, CV</name>
      <address>
        <city>Fukuoka, Koga</city>
        <zip>811-3195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Koga Hospital</name>
      <address>
        <city>Fukuoka, Kurume</city>
        <zip>830-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gumma Prefectural Cardiovascular Center</name>
      <address>
        <city>Gunma, Maebashi</city>
        <zip>371-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Takasaki General Medical Center</name>
      <address>
        <city>Gunma, Takasaki</city>
        <zip>370-0829</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuyama Cardiovascular Hospital</name>
      <address>
        <city>Hiroshima, Fukuyama</city>
        <zip>720-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokeidai Memorial Hospital</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <zip>060-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Medical Center</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Brain and Heart Center</name>
      <address>
        <city>Hyogo, Himeji</city>
        <zip>670-0981</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Veritas Hospital</name>
      <address>
        <city>Hyogo, Kawanishi</city>
        <zip>666-0125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Hyogo, Kobe</city>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takahashi Hospital</name>
      <address>
        <city>Hyogo, Kobe</city>
        <zip>654-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kanazawa Medical Center</name>
      <address>
        <city>Ishikawa, Kanazawa</city>
        <zip>920-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital</name>
      <address>
        <city>Iwate, Morioka</city>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa Prefectural Central Hospital</name>
      <address>
        <city>Kagawa, Takamatsu</city>
        <zip>760-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Fujisawa Tokushukai Hospital</name>
      <address>
        <city>Kanagawa, Fujisawa</city>
        <zip>251-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital</name>
      <address>
        <city>Kanagawa, Sagamihara</city>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City Minato Red Cross Hospital</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <zip>231-8682</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazaki Medical Association Hospital</name>
      <address>
        <city>Miyazaki, Miyazaki</city>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Osaka, Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City Hospital Organization Osaka City General Hospital</name>
      <address>
        <city>Osaka, Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sayama General Clinic</name>
      <address>
        <city>Saitama, Sayama</city>
        <zip>350-1305</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Saitama National Hospital</name>
      <address>
        <city>Saitama, Wako</city>
        <zip>351-0102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kusatsu General Hospital</name>
      <address>
        <city>Shiga, Kusatsu</city>
        <zip>525-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omihachiman Community Medical Center</name>
      <address>
        <city>Shiga, Omihachiman</city>
        <zip>523-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokushima Red Cross Hospital</name>
      <address>
        <city>Tokushima, Komatsushima</city>
        <zip>773-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishiarai Heart Center Hospital</name>
      <address>
        <city>Tokyo, Adachi-ku</city>
        <zip>123-0845</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital</name>
      <address>
        <city>Tokyo, Bunkyo-ku</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minamino Heart Clinic</name>
      <address>
        <city>Tokyo, Hachioji</city>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University Hospital</name>
      <address>
        <city>Tokyo, Itabashi-Ku</city>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital</name>
      <address>
        <city>Tokyo, Itabashi-Ku</city>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Itabashi Chuo Medical Center</name>
      <address>
        <city>Tokyo, Itabashi-Ku</city>
        <zip>174-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Health and Medicine Ctr</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>612-896</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National Univ. Hosp</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>705-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National Univ. Hosp</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Carollo Hospital</name>
      <address>
        <city>Suncheon</city>
        <zip>540-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hosp</name>
      <address>
        <city>Wonju</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cardiologica Aguascalientes</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiologia Ignacio Chavez</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Central Dr Ignacio M. P.</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Especializado en Terapia Endovascular (CETEN)</name>
      <address>
        <city>Zapopan, Jalisco</city>
        <zip>45040</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noordwest Ziekenhuisgroep</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scheper Ziekenhuis</name>
      <address>
        <city>Emmen</city>
        <zip>7824 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Admiraal de Ruyter Ziekenhuis</name>
      <address>
        <city>Goes</city>
        <zip>4462 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius ziekenhuis, locatie Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Bernhoven Uden</name>
      <address>
        <city>Uden</city>
        <zip>5406 PT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sørlandet sykehus HF, Avd. Arendal</name>
      <address>
        <city>Arendal</city>
        <zip>N-4838</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF, Ullevål sykehus</name>
      <address>
        <city>Oslo</city>
        <zip>N-0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger Helseforskning</name>
      <address>
        <city>Stavanger</city>
        <zip>N-4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssykehuset Nord-Norge, Tromsø</name>
      <address>
        <city>Tromsø</city>
        <zip>N-9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Clinic Hosp, Bialystok</name>
      <address>
        <city>Bialystok</city>
        <zip>15276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10.Military Clin.Hospital&amp;Polyclinic</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85681</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swissmed Vascular Sp. Z.o.o Hosp., Cardiology Dept., Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80215</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center, Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reg.Hosp Kielce,Swietokrzyskie,1.Clinic of Cardiology,Kielce</name>
      <address>
        <city>Kielce</city>
        <zip>25736</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Public Clin.Hosp.#4, Cardiology Clinic,Lubilin</name>
      <address>
        <city>Lublin</city>
        <zip>20954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Public Healthcare, Dept. of Cardiology, Pulawy</name>
      <address>
        <city>Pulawy</city>
        <zip>24100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Medical Academy, Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lower Silesian Spec.Hosp.T.Marciniaka,Cardiology Dep,Wroclaw</name>
      <address>
        <city>Wroclaw</city>
        <zip>54049</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Paul II Regional Hospital, Zamosc</name>
      <address>
        <city>Zamosc</city>
        <zip>22400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Garcia de Orta, EPE</name>
      <address>
        <city>Almada</city>
        <zip>2805-267</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUC - Centro Hospitalar e Universitário de Coimbra, EPE</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hosp. de Leiria-Pombal</name>
      <address>
        <city>Leiria</city>
        <zip>2410-197</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHLC, EPE - Hospital de Santa Marta</name>
      <address>
        <city>Lisboa</city>
        <zip>1169-024</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHLO, EPE - Hospital de Santa Cruz</name>
      <address>
        <city>Lisboa</city>
        <zip>1495-005</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHLN, EPE - Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUC,EPE - Hospital Geral dos Covões</name>
      <address>
        <city>S. Martinho Do Bispo,Coimbra</city>
        <zip>3041-801</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altaiskyi Reg.Cardiologic Dispensary,Cardiology Dept,Barnaul</name>
      <address>
        <city>Barnaul</city>
        <zip>656055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital No.3, Cardiology Dept,Chelyabinsk</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cent.f.Spec.Med.C.U.Cardi.Inst</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620144</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Instit.Kazan Fed.Univ.</name>
      <address>
        <city>Kazan</city>
        <zip>420043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Healthc Insti City Clin Hosp#7,Cardio,Kazan</name>
      <address>
        <city>Kazan</city>
        <zip>420103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Res.Inst.-Compl.Iss.Cardi.Dis.</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clin.Hosp.#1na S.V.Ochapovskiy</name>
      <address>
        <city>Krasnodar</city>
        <zip>350086</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clin.Hosp.#15 n.a.O.M.Filatov,Cardiology Dept.#2,Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>111 539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clin.Hosp#51,Moscow Healthcare Dep.X-ray surgery method</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cntr of CV Surgery na Bakulev,Surg.Treatm of Inter.Path.dept</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Pokrovskiy Hospital, Cardiology Dept., Saint Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199 106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budg.Healthc.Instit.Samara Reg.Clin.Cardiology Dispens</name>
      <address>
        <city>Samara</city>
        <zip>443070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-Western Fed.Med.Resear.Centr na V.I.Almazov,Cardio.dep</name>
      <address>
        <city>St.Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budg.Healthc.Instit Volgograd RegClin.Cardiology Centr</name>
      <address>
        <city>Volgograd</city>
        <zip>400008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Center</name>
      <address>
        <city>Singapore</city>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slov.Ins.Crdi.Dise.,Cor.C.U.</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nat.Instit.Cardiov.Diseas,Arryhythmias&amp;Cardiac Pacing,Bratis</name>
      <address>
        <city>Bratislava</city>
        <zip>83348</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Slovak Inst.Cardi.Disea.</name>
      <address>
        <city>Kosice</city>
        <zip>04011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiocentrum Nitra,Internal Medicine Dept, Nitra</name>
      <address>
        <city>Nitra</city>
        <zip>94901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Celje</name>
      <address>
        <city>Celje</city>
        <zip>3000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Izola, Cardiology Department</name>
      <address>
        <city>Izola</city>
        <zip>6310</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Medical Center Maribor</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>L'Hospitalet Llobregat (bcn)</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Manises</name>
      <address>
        <city>Manises</city>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Parc Taulí</name>
      <address>
        <city>Sabadell (Barcelona)</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao</name>
      <address>
        <city>Vizcaya</city>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Länssjukhuset, Gävle</name>
      <address>
        <city>Gävle</city>
        <zip>801 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset, Östra</name>
      <address>
        <city>Göteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Länssjukhuset, Halmstad</name>
      <address>
        <city>Halmstad</city>
        <zip>301 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lasarettet, Helsingborg</name>
      <address>
        <city>Helsingborg</city>
        <zip>251 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset, Linköping</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes universitetssjukhus, Lund</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes universitetssjukhus, Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyds Sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Hua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>824</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCKUH</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipe Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital(TaoYuan)</name>
      <address>
        <city>Taoyuan</city>
        <zip>330</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10170</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova Universitesi Tip Fakultesi Kardiyoloji AnabilimDali</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Türkiye Yüksek Ihtisas Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diskapi Yildirim Beyazit EAH</name>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bursa Yuksek Ihtisas EAH</name>
      <address>
        <city>Bursa</city>
        <zip>16330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Kardiyoloji Enstitusu</name>
      <address>
        <city>Istanbul</city>
        <zip>34096</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa Tip Fakultesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bagcilar Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medipol Mega Üniversitesi Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Mehmet Akif Ersoy Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siyami Ersek Gogus Kalp ve Damar Cerrahisi Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34668</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kartal Kosuyolu Yuksek Ihtisas EAH</name>
      <address>
        <city>Istanbul</city>
        <zip>34846</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Unv. Tip Fakultesi</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Izmir Katip Celebi Univ. EAH</name>
      <address>
        <city>Izmir</city>
        <zip>35360</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erciyes Universitesi Tip Fakultesi Kardiyoloji Anabilim Dali</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayis Universitesi Tip Fakultesi</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham City Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B18 7QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth and Christchurch Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorset County Hospital</name>
      <address>
        <city>Dorchester</city>
        <zip>DT1 2JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grantham District Hospital</name>
      <address>
        <city>Grantham</city>
        <zip>NG31 8DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wycombe General Hospital</name>
      <address>
        <city>High Wycombe</city>
        <zip>HP11 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln County Hospital</name>
      <address>
        <city>Lincoln</city>
        <zip>LN2 5QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altnagelvin Area Hospital</name>
      <address>
        <city>Londonderry</city>
        <zip>BT47 6SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke-on-Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>El Salvador</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>June 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2014</study_first_posted>
  <results_first_submitted>June 5, 2018</results_first_submitted>
  <results_first_submitted_qc>July 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2018</results_first_posted>
  <last_update_submitted>July 27, 2018</last_update_submitted>
  <last_update_submitted_qc>July 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02164864/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02164864/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients aged ≥80 years in the United States of America (USA) were assigned to 110 milligram (mg) Dual antithrombotic therapy with dabigatran etexilate (DE-DAT), 150 mg DE-DAT, or warfarin. All other patients including aged ≥80 years (for Japan ≥70 years) outside of the USA were assigned to 110 mg DE-DAT or warfarin</recruitment_details>
      <pre_assignment_details>All patients (Pts) were screened for eligibility to participate in trial. Pts attended sites to ensure that they met all implemented inclusion/exclusion criteria. Pts were not to be randomised to trial drug if any of specific entry criteria was violated. In this study, 2725 Pts were entered &amp; randomised. 2678 Pts were treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran Etexilate 110mg</title>
          <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Dabigatran Etexilate 150mg</title>
          <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Warfarin</title>
          <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="981">Started are the Randomised/entered patients.</participants>
                <participants group_id="P2" count="763">Started are the Randomised/entered patients.</participants>
                <participants group_id="P3" count="981">Started are the Randomised/entered patients.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="886"/>
                <participants group_id="P2" count="703"/>
                <participants group_id="P3" count="849"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="132"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Trial disease worsening</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other pre-existing disease worsening</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Adverse Event (AE)</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn, not due to AE</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than stated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The anaysis set used was Full analysis set (FAS)</population>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran Etexilate 110mg</title>
          <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Dabigatran Etexilate 150mg</title>
          <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Warfarin</title>
          <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="981"/>
            <count group_id="B2" value="763"/>
            <count group_id="B3" value="981"/>
            <count group_id="B4" value="2725"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at the time of signing informed consent form is presented.</description>
          <population>FAS</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.5" spread="8.87"/>
                    <measurement group_id="B2" value="68.6" spread="7.65"/>
                    <measurement group_id="B3" value="71.7" spread="8.90"/>
                    <measurement group_id="B4" value="70.8" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;80: EU/ROW</title>
                  <measurement_list>
                    <measurement group_id="B1" value="725"/>
                    <measurement group_id="B2" value="699"/>
                    <measurement group_id="B3" value="718"/>
                    <measurement group_id="B4" value="2142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt;80: USA</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="168"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥80: EU/ROW</title>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="384"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥80: USA</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="231"/>
                    <measurement group_id="B4" value="655"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="728"/>
                    <measurement group_id="B2" value="592"/>
                    <measurement group_id="B3" value="750"/>
                    <measurement group_id="B4" value="2070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="903"/>
                    <measurement group_id="B2" value="700"/>
                    <measurement group_id="B3" value="904"/>
                    <measurement group_id="B4" value="2507"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>The details on Race has been provided</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="851"/>
                    <measurement group_id="B2" value="658"/>
                    <measurement group_id="B3" value="835"/>
                    <measurement group_id="B4" value="2344"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Adjudicated ISTH MBE or CRNMBE</title>
        <description>Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported.
Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial.
Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status.
Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'.</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA)</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Adjudicated ISTH MBE or CRNMBE</title>
          <description>Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported.
Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial.
Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status.
Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'.</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="154"/>
                    <measurement group_id="O3" value="264"/>
                    <measurement group_id="O4" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A pre-defined hierarchical testing approach was used. This was the first step in hierarchy. The upper bound of the Wald confidence interval (CI) of the HR of Dabigatran Etexilate 110mg vs Warfarin (one-sided 97.5%) was compared with this noninferiority margin for the testing of non-inferiority.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>All non-inferiority tests were based on a margin of 1.38.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P values for noninferiority were calculated at a one-sided alpha level of 0.025</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A pre-defined hierarchical testing approach was used. This was the second step in hierarchy. The upper bound of the Wald confidence interval (CI) of the HR of Dabigatran Etexilate 150mg vs Warfarin (one-sided 97.5%) was compared with this noninferiority margin for the testing of non-inferiority</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>All non-inferiority tests were based on a margin of 1.38.</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>P-values for non-inferiority were calculated at a one-sided alpha level of 0.025</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A pre-defined hierarchical testing approach was used. This was the fourth step in hierarchy.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A pre-defined hierarchical testing approach was used. This was the sixth step in hierarchy.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0020</p_value>
            <p_value_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <other_analysis_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Adjudicated Undetermined Cause of Death</title>
        <description>Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported.
This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was &quot;patient died&quot;) or when there was insufficient supporting information or detail to assign the cause of death.</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA)</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Adjudicated Undetermined Cause of Death</title>
          <description>Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported.
This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was &quot;patient died&quot;) or when there was insufficient supporting information or detail to assign the cause of death.</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9862</p_value>
            <p_value_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>3.95</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</non_inferiority_desc>
            <p_value>0.5277</p_value>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded from</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>6.64</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Adjudicated Non-CV</title>
        <description>Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported.
Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA)</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Adjudicated Non-CV</title>
          <description>Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported.
Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8853</p_value>
            <p_value_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2380</p_value>
            <p_value_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded from</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Adjudicated CV</title>
        <description>Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported.
CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes.</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA)</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Adjudicated CV</title>
          <description>Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported.
CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes.</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5252</p_value>
            <p_value_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5670</p_value>
            <p_value_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded from</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Adjudicated All Cause Death</title>
        <description>Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death.</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA)</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Adjudicated All Cause Death</title>
          <description>Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death.</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5579</p_value>
            <p_value_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4414</p_value>
            <p_value_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Adjudicated MI</title>
        <description>Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA)</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Adjudicated MI</title>
          <description>Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</non_inferiority_desc>
            <p_value>0.0861</p_value>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6144</p_value>
            <p_value_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded from</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Adjudicated Stroke</title>
        <description>Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported.
Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA)</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Adjudicated Stroke</title>
          <description>Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported.
Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4803</p_value>
            <p_value_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>2.67</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8537</p_value>
            <p_value_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded from</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>2.83</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Adjudicated SE</title>
        <description>Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported.
SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy.</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA)</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Adjudicated SE</title>
          <description>Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported.
SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy.</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9388</p_value>
            <p_value_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>4.66</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3030</p_value>
            <p_value_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded from</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>2.93</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Adjudicated ST</title>
        <description>Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported.</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA)</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Adjudicated ST</title>
          <description>Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported.</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1546</p_value>
            <p_value_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>4.40</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9789</p_value>
            <p_value_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded from</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>2.81</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Composite Endpoint of Death + MI + Stroke</title>
        <description>Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported.</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA)</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Composite Endpoint of Death + MI + Stroke</title>
          <description>Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported.</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0484</p_value>
            <p_value_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8903</p_value>
            <p_value_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded from</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Composite Endpoint of Death or First Thrombotic Event</title>
        <description>Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE).</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
          <group group_id="O5">
            <title>All Dabigatran Etexilate</title>
            <description>Patients in combined Dabigatran Etexilate group (ie 110 mg DE + 150 mg DE).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Composite Endpoint of Death or First Thrombotic Event</title>
          <description>Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE).</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
                <count group_id="O5" value="1744"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="60"/>
                    <measurement group_id="O5" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A pre-defined hierarchical testing approach was used. This was the fifth step in hierarchy.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>All non-inferiority tests were based on a margin of 1.38.</non_inferiority_desc>
            <p_value>0.1128</p_value>
            <p_value_desc>P values for noninferiority were calculated at a one-sided alpha level of 0.025</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
            <estimate_desc>The upper bound of the Wald confidence interval (CI) of the HR of All Dabigatran Etexilate (110mg and 150 mg) vs Warfarin (one-sided 97.5%) was compared with this noninferiority margin for the testing of non-inferiority</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0720</p_value>
            <p_value_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8750</p_value>
            <p_value_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Adjudicated Unplanned Revascularisation by PCI/CABG</title>
        <description>Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported.</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA)</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Adjudicated Unplanned Revascularisation by PCI/CABG</title>
          <description>Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported.</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6080</p_value>
            <p_value_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8348</p_value>
            <p_value_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded from</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG</title>
        <description>Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported.</description>
        <time_frame>up to 30 months</time_frame>
        <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate 110mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran Etexilate 150mg</title>
            <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin</title>
            <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
          </group>
          <group group_id="O4">
            <title>Warfarin (Excluding Elder Patients Outside USA)</title>
            <description>Patients were orally administered warfarin once daily. The warfarin dose was titrated as needed to maintain the target INR of 2.0 to 3.0 ; 2.0 to 2.5 if feasible. Elderly patients who were outside the USA were excluded.</description>
          </group>
          <group group_id="O5">
            <title>All Dabigatran Etexilate</title>
            <description>Patients in combined Dabigatran Etexilate group (ie 110 mg DE + 150 mg DE).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG</title>
          <description>Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported.</description>
          <population>Full Analysis set (FAS) following the intention-to-treat principle.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="981"/>
                <count group_id="O2" value="763"/>
                <count group_id="O3" value="981"/>
                <count group_id="O4" value="764"/>
                <count group_id="O5" value="1744"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="131"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>A pre-defined hierarchical testing approach was used. This was the third step in hierarchy.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>All non-inferiority tests were based on a margin of 1.38.</non_inferiority_desc>
            <p_value>0.0047</p_value>
            <p_value_desc>P values for noninferiority were calculated at a one-sided alpha level of 0.025</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>The upper bound of the Wald confidence interval (CI) of the HR of All Dabigatran Etexilate (110mg and 150 mg) vs Warfarin (one-sided 97.5%) was compared with this noninferiority margin for the testing of non-inferiority</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3002</p_value>
            <p_value_desc>Wald 2-sided p-value from (stratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The Cox proportional hazard model is stratified by age, non−elderly vs elderly [&lt;70 or &gt;=70 in Japan and &lt;80 or &gt;=80 years old elsewhere].</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4432</p_value>
            <p_value_desc>Wald 2-sided p-value from (unstratified) Cox proportional hazards model</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first intake of randomised trial drug until 6 days after the last intake of the randomised trial drug, ie., up to 31 Months.</time_frame>
      <desc>Treated set (TS): The set of patients who received at least 1 dose of trial medication was analysed according to the treatment they had received. The start date of the observation period for this analysis set was the date of the first intake of trial medication.
All on-treatement AE's for this study were reported based on the Treated set</desc>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran Etexilate 110mg</title>
          <description>Patients were orally administered Dabigatran Etexilate 110mg capsule twice daily (BID) for at least 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Dabigatran Etexilate 150mg</title>
          <description>Patients were orally administered Dabigatran Etexilate 150mg capsule twice daily (BID) for at least 6 months.</description>
        </group>
        <group group_id="E3">
          <title>Warfarin</title>
          <description>Patients were orally administered warfarin 1 mg, 3 mg, or 5 mg tablets once daily for at least 6 months. The warfarin dose was titrated as needed to maintain the target International normalised ratio (INR) of 2.0 to 3.0 (2.0 to 2.6 for Japanese patients aged ≥70 years); 2.0 to 2.5 if feasible</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="415" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="300" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="396" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Acute right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Myocardial fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ventricle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Generalised resistance to thyroid hormone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Venous angioma of brain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness transient</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dental cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gastrointestinal polyp haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Rectal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Stomach mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Device related thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Drug effect increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Implant site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Medical device site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vascular stent stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vascular stent thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Biliary cirrhosis primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bone abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Diverticulitis intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Arterial bypass occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Chemical burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Confusion postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Iatrogenic injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Postoperative renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Postoperative thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Blood pressure abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Blood urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hyperhomocysteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Metabolic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Plica syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Benign gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Carcinoma in situ of penis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cerebral haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Testicular neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Tumour ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Urinary bladder adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Basal ganglia stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Diplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Drop attacks</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Encephalomalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lateral medullary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Transient psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Aortic dissection rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Aortic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Aortitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Femoral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="229" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="948"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="146" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="972"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="758"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="948"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

